Cargando…
Response to “Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA PRO Guidance”
Autores principales: | Ascher, Benjamin, Rzany, Berthold, Kestemont, Philippe, Hilton, Said, Heckmann, Marc, Bodokh, Isaac, Noah, Ernst Magnus, Boineau, Dominique, Kerscher, Martina, Volteau, Magali, Le Berre, Philippe, Picaut, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676453/ https://www.ncbi.nlm.nih.gov/pubmed/32960940 http://dx.doi.org/10.1093/asj/sjaa240 |
Ejemplares similares
-
Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial
por: Ascher, Benjamin, et al.
Publicado: (2020) -
Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines
por: Ascher, Benjamin, et al.
Publicado: (2019) -
Corrigendum to: Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines
por: Ascher, Benjamin, et al.
Publicado: (2021) -
Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA Patient-Reported Outcome Guidance
por: Patel, Vaishali, et al.
Publicado: (2020) -
Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study
por: Kestemont, Philippe, et al.
Publicado: (2021)